• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Azilect - Analysis and Estimates from 2005 to 2020 Product Image

Azilect - Analysis and Estimates from 2005 to 2020

  • Published: July 2011
  • 36 pages
  • GlobalData

Azilect – Analysis and Estimates from 2005 to 2020

Summary

GlobalData’s pharmaceuticals report, “Azilect – Analysis and Estimates from 2005 to 2020” provides Azilect sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Azilect including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Parkinson’s Disease
2.2 Symptoms of Parkinson’s Disease
2.3 Diagnosis of Parkinson’s disease
2.4 Parkinson’s Disease Treatment Strategies
2.5 Parkinson’s Disease Market
2.6 Epidemiology
2.7 Parkinson’s Disease by Age and Gender
2.8 Etiology
2.9 GlobalData Report Guidance
3 Parkinson’s Disease: Market Characterization
3.1 Parkinson’s Disease Market
3.2 Parkinson’s Disease Market Forecasts and CAGR
3.3 Factors Affecting Parkinson’s Disease Market
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder
3.3.2 Increase in Old Age Population
3.3.3 Patent Expiry of Prominent Drugs
4 Stages of Parkinson’s Disease and Comparison of Treatments
4.1 The Hoehn and Yahr Scale
4.2 Modified Hoehn and Yahr Scale
4.3 The UPDRS
5 Staging of Parkinson’s Disease
5.1 Distribution of Parkinson’s disease Patients by Age Groups
5.2 Distribution of Patients by Stages
6 Azilect
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.3.1 Monotherapy
6.3.2 Adjunct to Levodopa
6.4 Approval History of Azilect
6.5 Factors Affecting Sales of Azilect
6.5.1 Used in Multiple Regimens
6.5.2 Unmet need
6.5.3 Better Safety Profile than Levodopa, Current SOC
6.5.4 Strong Patent Protection
6.5.5 Better presence in the market
6.5.6 Better Compliance
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Estimates
6.7.1 Target Patient Pool of Azilect
6.7.2 Market Penetration
6.7.3 Dosing
6.7.4 Annual Cost of Therapy
6.7.5 Sales Estimates of Azilect
7 Parkinson Disease Market: Appendix
7.1 Market Definitions
7.2 List of Abberiviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.3.8 Primary Research
7.3.9 Expert Panels
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

1.1 List of Tables
Table 1: Clinical Motor and Nonmotor Features of Parkinson’s Disease
Table 2: Hoehn and Yahr Stages of Parkinson’s Disease
Table 3: Hoehn and Yahr Stages of Parkinson’s Disease
Table 4: Four Items, Part 1 of UPDRS
Table 5: Thirteen Items, Part 2 of Parkinson’s disease
Table 6: Fourteen Items, Part 3 of UPDRS
Table 7: Fourteen Items, Part 3 of UPDRS
Table 8: Distribution of Parkinson’s patients according to Hoehn and Yahr Classification
Table 9: UPDRS Score for Azilect as Monotherapy
Table 10: Change in Mean Total Daily “OFF” Time
Table 11: UPDRS ADL (Activities of Daily Living) Subscale Score while “OFF”
Table 12: UPDRS Motor Subscale Score while “ON”
Table 13: Approval History of Azilect
Table 14: Drug Risk Benefit Score (DRB)-Azilect
Table 15: Efficacy Comparison of Azilect
Table 16: Annual Cost of Azilect for Parkinson’s Disease, 2011
Table 17: Azilect, Parkinson’s Disease, Global, Sales Estimates ($m), 2005–2020
Table 18: Azilect, Parkinson’s Disease, The US, Sales Estimates ($m), 2006–2020
Table 19: Azilect, Parkinson’s Disease, UK, Sales Estimates ($m), 2005–2020
Table 20: Azilect, Parkinson’s Disease, France, Sales Estimates ($m), 2006–2020
Table 21: Azilect, Parkinson’s Disease, Germany, Sales Estimates ($m), 2005–2020
Table 22: Azilect, Parkinson’s Disease, Italy, Sales Estimates ($m), 2007–2020
Table 23: Azilect, Parkinson’s Disease, Spain, Sales Estimates ($m), 2006–2020
Table 24: Azilect, Parkinson’s Disease, Japan, Sales Estimates ($m), 2006–2020

1.2 List of Figures
Figure 1: Current Pharmacologic Therapies for Parkinson’s disease and Their Potential Sites of Action in the CNS
Figure 2: The Age-Specific Prevalence Rates of Parkinson’s Disease in the Elderly Among Five European Countries, 2003
Figure 3: Parkinson’s Disease, Global, Market Size Estimates ($bn), 2010–2020
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
Figure 5: Points Distribution of UPDRS
Figure 6: Distribution of Parkinson’s patients by Hoehn & Yahr Classification
Figure 7: Drug Model Diagram of Azilect in the US, EU and Japan
Figure 8: Azilect, Parkinson’s Disease, Global, Sales Estimates ($m), 2005–2020
Figure 9: Azilect, Parkinson’s Disease, The US, Sales Estimates ($m), 2006–2020
Figure 10: Azilect, Parkinson’s Disease, The UK, Sales Estimates ($m), 2005–2020
Figure 11: Azilect, Parkinson’s Disease, France, Sales Estimates ($m), 2006–2020
Figure 12: Azilect, Parkinson’s Disease, Germany, Sales Estimates ($m), 2005–2020
Figure 13: Azilect, Parkinson’s Disease, Italy, Sales Estimates ($m), 2007–2020
Figure 14: Azilect, Parkinson’s Disease, Spain, Sales Estimates ($m), 2006–2020
Figure 15: Azilect, Parkinson’s Disease, Japan, Sales Estimates ($m), 2006–2020
Figure 16: Azilect, Type 2 Diabetes, Sales Distribution by Country (%), 2016
Figure 17: Drug Model Diagram
Figure 18: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos